News

1 2 3 4 5 6
NEWS

SOTIO starts Phase I/II trial of DCVAC in combination with ONCOS-102: the Targovax adenovirus based immunotherapy

SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming engineered human serotype 5 adenovirus, for patients with prostate cancer. The trial is planned for the United Kingdom and the Czech Republic. SOTIO is collaborating with Targovax,a clinical stage immuno-oncology company developing ONCOS-102.

NEWS

SOTIO completes enrollment of phase III VIABLE study in late stage prostate cancer

SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the last patient into the VIABLE study, a global Phase III clinical trial evaluating DCVAC/PCa in combination with docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC).

NEWS

SOTIO Presents its Clinical Development Program at the 2016 American Society for Clinical Oncology (ASCO) Annual Meeting

SOTIO, a biotechnology company owned by the PPF Group, presents its clinical development program of DCVAC medicinal products at the 2016 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. DCVAC is an active cellular immunotherapy treatment for patients with cancer. SOTIO attends ASCO 2016 (June 3 to June 7, 2016) with its own exhibition booth and presents its 10 running clinical trials to expert community.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies